InvestorsHub Logo
Followers 126
Posts 4599
Boards Moderated 0
Alias Born 10/20/2001

Re: None

Sunday, 09/22/2019 8:54:43 AM

Sunday, September 22, 2019 8:54:43 AM

Post# of 8311
"TENX IS THE REAL DEAL, INVESTORS SHOULD NOT BE SLEEPING ON THIS SILENT GIANT!"

Evaluation of Levosimendan in Patients with PH-HFpEF). There are currently 12 activated sites, with an additional three sites expected to be activated over the next few weeks, which we believe will be sufficient to fully enroll the trial. Eight patients, up from three at the end of June, are currently enrolled out of the targeted 36 patients. Three of the eight patients have completed the initial 6-week HELP protocol and have rolled over into the 2-year extension phase

TENX!! READ BETWEEN THE LINES HERE!!! Just going over my DD on ALL of my investments this morning as I always do from time to time, just to double check and make sure that I still FEEL GREAT ABOUT WHERE I have invested my resources! TENX, COULDN'T FEEL BETTER!!! Anthony DiTonno, CEO of Tenax Therapeutics, commented, “We are pleased with the progress made over the past few months to advancing the Phase 2 trial. Based on feedback from our principal investigators we have modified and adapted our protocols for the HELP trial. These modifications, in addition to achieving our targeted number of clinical sites, have resulted in an acceleration in the pace of patient enrollment. Given the momentum in the quarter, we now expect full enrollment and top-line data in the HELP Trial in the first quarter of 2020. We are also pleased to announce that the company has developed and recently filed a patent application for a subcutaneous formulation of levosimendan. Future development activities will be finalized following the completion of our phase 2 HELP trial and subsequent discussion with the FDA on a phase 3 trial for PH-HFpEF patients.” MBD
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent TENX News